ASLAN Pharmaceuticals Limited - American Depositary Shares (ASLN)
ASLN moved a median of -1.96% 30 minutes after news, and -2.12% by the close. How ASLN actually reacts to news — the realized, point-in-time move the market made, measured across 67 labeled events over the last three years with zero look-ahead.
ASLN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.84% | 35% | 58 |
| 30-min | -1.96% | 36% | 64 |
| 60-min | -2.13% | 36% | 64 |
| to close | -2.12% | 31% | 64 |
| Middle 50% of ASLN reactions | -2.73% to +0.90% |
|---|---|
| Median reaction (30-min) | -1.96% |
| Measured reactions | 67 |
Half of all ASLAN Pharmaceuticals Limited - American Depositary Shares news events land between -2.73% and +0.90% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ASLN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ASLN's baseline. Nothing else.
Recent ASLN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Press release | PR Newswire | — | — | |
| Hummingbird Bioscience Announces Key Leadership Appointments | Press release | GlobeNewswire | — | — | |
| ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation | Press release | GlobeNewswire | -7.43% | +32.06% | |
| Form 6-K ASLAN Pharmaceuticals For: Jul 17 | SEC filing · Form 6-K | SEC EDGAR | -7.43% | +32.06% | |
| ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal | Press release | GlobeNewswire | +14.51% | +5.34% | |
| Form 6-K ASLAN Pharmaceuticals For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | +14.51% | +5.34% | |
| Form EFFECT ASLAN Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | -1.56% | -8.37% | |
| ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change | Press release | GlobeNewswire | +0.25% | -9.75% | |
| Form 6-K ASLAN Pharmaceuticals For: Jun 14 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | -9.75% | |
| Form F-3 ASLAN Pharmaceuticals | SEC filing · Form F-3 | SEC EDGAR | -0.96% | -3.81% | |
| Form 6-K ASLAN Pharmaceuticals For: May 31 | SEC filing · Form 6-K | SEC EDGAR | -4.54% | +2.23% | |
| ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference | Press release | GlobeNewswire | -1.96% | -5.88% | |
| ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -0.05% | |
| Form 6-K ASLAN Pharmaceuticals For: May 09 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.05% | |
| ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event | Press release | GlobeNewswire | +6.63% | -2.11% | |
| Form 6-K ASLAN Pharmaceuticals For: May 07 | SEC filing · Form 6-K | SEC EDGAR | +6.63% | -2.11% | |
| ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics | Press release | GlobeNewswire | +2.31% | -0.95% | |
| ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab | Press release | GlobeNewswire | -0.74% | -2.13% | |
| ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference | Press release | GlobeNewswire | +5.75% | +0.00% | |
| ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients | Press release | GlobeNewswire | -13.77% | -24.54% | |
| Form 6-K ASLAN Pharmaceuticals For: Apr 22 | SEC filing · Form 6-K | SEC EDGAR | -13.77% | -24.54% | |
| ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice | Press release | GlobeNewswire | -13.77% | -24.54% | |
| Form 6-K ASLAN Pharmaceuticals For: Apr 19 | SEC filing · Form 6-K | SEC EDGAR | -13.77% | -24.54% | |
| ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.52% | -8.17% | |
| Form 20-F ASLAN Pharmaceuticals For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -2.52% | -8.17% | |
| Form 6-K ASLAN Pharmaceuticals For: Apr 12 | SEC filing · Form 6-K | SEC EDGAR | -2.52% | -8.17% | |
| Form S-8 ASLAN Pharmaceuticals | SEC filing · Form S-8 | SEC EDGAR | -2.52% | -8.17% | |
| Form EFFECT ASLAN Pharmaceuticals | SEC filing · Form EFFECT | SEC EDGAR | -1.16% | -1.56% | |
| Form D ASLAN Pharmaceuticals | SEC filing · Form D | SEC EDGAR | +0.00% | +0.85% | |
| Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders | Press release | GlobeNewswire | +3.34% | +0.32% | |
| Form F-3 ASLAN Pharmaceuticals | SEC filing · Form F-3 | SEC EDGAR | -0.92% | -2.31% | |
| Form 6-K ASLAN Pharmaceuticals For: Mar 13 | SEC filing · Form 6-K | SEC EDGAR | +1.39% | +5.62% | |
| ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering | Press release | GlobeNewswire | -20.62% | -46.69% | |
| ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients | Press release | GlobeNewswire | +9.98% | +160.38% | |
| Form 6-K ASLAN Pharmaceuticals For: Mar 11 | SEC filing · Form 6-K | SEC EDGAR | +9.98% | +160.38% | |
| ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors | Press release | GlobeNewswire | -12.25% | -9.83% | |
| ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat | Press release | GlobeNewswire | +0.30% | +22.22% | |
| Form 6-K ASLAN Pharmaceuticals For: Jan 24 | SEC filing · Form 6-K | SEC EDGAR | -4.97% | -10.95% | |
| ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement | Press release | GlobeNewswire | -2.75% | +10.40% | |
| Form 6-K ASLAN Pharmaceuticals For: Jan 08 | SEC filing · Form 6-K | SEC EDGAR | -2.75% | +10.40% | |
| ASLAN Pharmaceuticals Announces Participation in January Investor Conferences | Press release | GlobeNewswire | -1.52% | +5.77% | |
| Form 6-K ASLAN Pharmaceuticals For: Dec 23 | SEC filing · Form 6-K | SEC EDGAR | -4.65% | -8.61% | |
| ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs | Press release | GlobeNewswire | +0.00% | -6.00% | |
| Form 6-K ASLAN Pharmaceuticals For: Dec 09 | SEC filing · Form 6-K | SEC EDGAR | +2.75% | -0.98% | |
| ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference | Press release | GlobeNewswire | +0.00% | -0.96% | |
| ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit | Press release | GlobeNewswire | +6.62% | +4.76% | |
| Spinal Cord Injury Market Likely to Exhibit Substantial Growth by 2032, Assesses DelveInsight | Companies to Watch Out - NervGen Pharma, StemCyte, Mitsubishi Tanabe Pharma America, AbbVie | Press release | PR Newswire | — | -4.50% | |
| ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | -7.39% | |
| Form 6-K ASLAN Pharmaceuticals For: Oct 27 | SEC filing · Form 6-K | SEC EDGAR | — | -7.39% | |
| ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis | Press release | GlobeNewswire | — | +3.45% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ASLN section they belong to.
Where else ASLN is measured.
ASLN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Medigus Ltd. - American Depositary Shares (MDGS) | 68 | -1.33% | 41% |
| AquaBounty Technologies, Inc. (AQB) | 67 | +0.01% | 51% |
| IMAGIN MEDICAL INC (IMEXF) | 67 | 0.00% | 25% |
| PRESSURE BIOSCIENCES (PBIO) | 67 | 0.00% | 27% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ASLAN Pharmaceuticals Limited - American Depositary Shares's median reaction calculated?
Every labeled ASLN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 67 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of ASLN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ASLN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.